kalkinemedia19h
Venezuela’s investment climate worsens amid political and economic turmoil
Venezuela’s once-promising investment landscape has drastically deteriorated, largely due to political turmoil and economic ...
kalkinemedia20h
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY®
HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – HETRONIFLY® (serplulimab) is expected to become the first anti-PD-1 ...
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult pati…
HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...
Medscape1d
Europe Recommends Lung Cancer Drug Hetronifly
Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...
The Pharma Letter1d
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
FiercePharma1d
Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...
Le Lézard5d
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further ...